Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …

And one special coin could do even better.

David Weber Biography and Net Worth

COO of Abiomed

Dr. David Weber joined Abiomed in April 2007 as the chief operating officer. Prior to joining Abiomed, Dr. Weber served as general manager, aviation business at GE Security—Homeland Protection from April 2005 until April 2007 where he led GE Security’s aviation and transportation business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as general manager, MRI marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as manager, global high field MRI business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber has a Bachelor of Science in physics from Denison University, a Bachelor of Science in nuclear engineering from Columbia University, and a Master of Science as well as a Doctor of Philosophy in medical physics from the University of Wisconsin-Madison.

What is David M. Weber's net worth?: The estimated net worth of David M. Weber is at least $44.32 million as of March 31st, 2022. Dr. Weber owns 116,314 shares of Abiomed stock worth more than $44,317,960 as of November 18th. This net worth evaluation does not reflect any other investments that Dr. Weber may own. Additionally, Dr. Weber receives a salary of $1,020,000.00 as COO at Abiomed. Learn More about David M. Weber's net worth.
How old is David M. Weber?: Dr. Weber is currently 62 years old. There are 6 older executives and no younger executives at Abiomed. Learn More on David M. Weber's age.
What is David M. Weber's salary?: As the COO of Abiomed, Inc., Dr. Weber earns $1,020,000.00 per year. The highest earning executive at Abiomed is Mr. Michael R. Minogue, Chairman, CEO & Pres, who commands a salary of $3,040,000.00 per year. Learn More on David M. Weber's salary.
How do I contact David M. Weber?: The corporate mailing address for Dr. Weber and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on David M. Weber's contact information.
Has David M. Weber been buying or selling shares of Abiomed?: David M. Weber has not been actively trading shares of Abiomed in the last ninety days. Most recently, David M. Weber sold 7,500 shares of the business's stock in a transaction on Thursday, March 31st. The shares were sold at an average price of $340.00, for a transaction totalling $2,550,000.00. Following the completion of the sale, the chief operating officer now directly owns 116,314 shares of the company's stock, valued at $39,546,760. Learn More on David M. Weber's trading history.
Who are Abiomed's active insiders?: Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

David M. Weber Insider Trading History at Abiomed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2022	Sell	7,500	$340.00	$2,550,000.00	116,314
2/9/2022	Sell	3,112	$310.19	$965,311.28
2/7/2022	Sell	300	$300.25	$90,075.00
8/5/2019	Sell	8,095	$206.26	$1,669,674.70	132,913
1/25/2019	Sell	24,000	$351.47	$8,435,280.00	161,842
7/30/2018	Sell	19,282	$356.77	$6,879,239.14	167,124
6/18/2018	Sell	46,500	$442.63	$20,582,295.00	189,657
7/31/2017	Sell	16,500	$147.63	$2,435,895.00	125,122
5/8/2017	Sell	21,250	$130.89	$2,781,412.50	123,771
5/23/2016	Sell	4,342	$96.97	$421,043.74	100,159
5/16/2016	Sell	5,604	$94.56	$529,914.24	116,783
5/6/2016	Sell	2,145	$93.82	$201,243.90	117,411
5/5/2016	Sell	52,000	$95.27	$4,954,040.00	121,676
3/24/2016	Sell	5,235	$89.93	$470,783.55	113,411
3/8/2016	Sell	17,521	$85.20	$1,492,789.20	125,761
3/7/2016	Sell	8,111	$85.21	$691,138.31	125,761
5/27/2015	Sell	17,968	$60.77	$1,091,915.36
5/6/2015	Sell	1,605	$73.72	$118,320.60
3/23/2015	Sell	3,765	$71.08	$267,616.20
5/27/2014	Sell	10,172	$21.11	$214,730.92
6/4/2013	Sell	6,519	$21.20	$138,202.80
5/28/2013	Sell	6,018	$22.18	$133,479.24

David M. Weber Buying and Selling Activity at Abiomed

Abiomed Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Today's Range

Now: $381.02

$381.02

50 Day Range

MA: $380.55

$377.20

$381.30

2 Week Range

Now: $381.02

$219.85

$381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4

Crypto’s next big bull run?

From Weiss Ratings | Ad